Insmed Incorporated
Clinical trials sponsored by Insmed Incorporated, explained in plain language.
-
Lifeline for lung patients: TPIP access extended
Disease control AVAILABLEThis study offers continued access to the inhaled drug TPIP for people with pulmonary arterial hypertension (PAH) or pulmonary hypertension linked to interstitial lung disease (PH-ILD) who have already completed a related study. Participants must have successfully finished prior …
Sponsor: Insmed Incorporated • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New inhaled drug could ease breathing for PAH patients
Disease control Recruiting nowThis phase 3 trial is testing whether a once-daily inhaled medication called treprostinil palmitil can help adults with pulmonary arterial hypertension (PAH) walk farther. About 344 participants will receive either the drug or a placebo for 24 weeks. The main goal is to see if th…
Phase: PHASE3 • Sponsor: Insmed Incorporated • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New inhaled drug aims to help lung patients breathe and move easier
Disease control Recruiting nowThis phase 3 trial tests an inhaled drug called treprostinil palmitil in 344 adults with pulmonary hypertension caused by interstitial lung disease. Participants take the drug or a placebo once daily for 24 weeks. The main goal is to see if the drug helps them walk farther in six…
Phase: PHASE3 • Sponsor: Insmed Incorporated • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC